Exclusive: Gene editing pioneer Feng Zhang launches new startup in Cambridge

Feng Zhang, the Broad Institute scientist credited with pioneering the field of gene editing, has quietly co-founded a new startup in Cambridge with backing from two prominent venture capital firms. Beam Therapeutics raised the first $13 million tranche of a Series A round in February from ARCH Venture Partners and F-Prime Capital, according to PitchBook. A person familiar with the matter said that the company has now received commitments totaling around $85 million as it prepares to come out of…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news